Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 7/2007

01-07-2007 | Metaanalysis

Diabetes mellitus and risk of endometrial cancer: a meta-analysis

Authors: E. Friberg, N. Orsini, C. S. Mantzoros, A. Wolk

Published in: Diabetologia | Issue 7/2007

Login to get access

Abstract

Aims/hypothesis

Diabetes has been associated with a statistically significantly increased risk of endometrial cancer in most, but not all studies. To provide a quantitative assessment of the association between diabetes and risk of endometrial cancer, we conducted a meta-analysis of case-control studies and cohort studies.

Subjects and methods

We identified studies by a literature search of PubMed and Embase through to January 2007 and by searching the reference lists of relevant articles. Summary relative risks (RRs) with 95% CIs were calculated using random-effects model.

Results

The analysis of diabetes (largely type 2) and endometrial cancer is based on 16 studies (three cohort and 13 case-control studies), including 96,003 participants and 7,596 cases of endometrial cancer. Twelve of the studies showed a statistically significantly increased risk and four a non-significant increased risk of endometrial cancer. In our meta-analysis we found that diabetes was statistically significantly associated with an increased risk of endometrial cancer (summary RR 2.10, 95% CI 1.75–2.53). The risk estimates were somewhat stronger among case-control (RR 2.22, 95% CI 1.80–2.74) than among cohort studies (RR 1.62, 95% CI 1.21–2.16), stronger among studies adjusting only for age (RR 2.74, 95% CI 1.87–4.00) compared with multivariate adjustment (RR 1.92, 95% CI 1.58–2.33) and slightly lower in studies performed in the USA than in those performed Europe. The analysis of type 1 diabetes and endometrial cancer was based on three studies and found a statistically significant positive association (summary RR 3.15, 95%CI 1.07–9.29).

Conclusions/interpretation

Results from the meta-analysis support a relationship between diabetes and increased risk of endometrial cancer.
Literature
1.
2.
Polednak AP (2003) Trends in incidence rates for obesity-associated cancers in the US. Cancer Detect Prev 27:415–421CrossRefPubMed
3.
Bray F, Dos Santos Silva I, Moller H, Weiderpass E (2005) Endometrial cancer incidence trends in Europe: underlying determinants and prospects for prevention. Cancer Epidemiol Biomarkers Prev 14:1132–1142CrossRefPubMed
4.
Kissebah AH, Vydelingum N, Murray R et al (1982) Relation of body fat distribution to metabolic complications of obesity. J Clin Endocrinol Metab 54:254–260PubMed
5.
6.
International Agency for Research on Cancer (2002) Weight control and physical activity. IARC, Lyon
7.
Schouten LJ, Goldbohm RA, van den Brandt PA (2004) Anthropometry, physical activity, and endometrial cancer risk: results from the Netherlands cohort study. J Natl Cancer Inst 96:1635–1638PubMedCrossRef
8.
Modesitt SC, van Nagell JR Jr (2005) The impact of obesity on the incidence and treatment of gynecologic cancers: a review. Obstet Gynecol Surv 60:683–692CrossRefPubMed
9.
Friberg E, Mantzoros CS, Wolk A (2007) Diabetes and risk of endometrial cancer: a population-based prospective cohort study. Cancer Epidemiol Biomarkers Prev 16:276–280CrossRefPubMed
10.
Weiss JM, Saltzman BS, Doherty JA et al (2006) Risk factors for the incidence of endometrial cancer according to the aggressiveness of disease. Am J Epidemiol 164:56–62CrossRefPubMed
11.
Weiderpass E, Persson I, Adami HO, Magnusson C, Lindgren A, Baron JA (2000) Body size in different periods of life, diabetes mellitus, hypertension, and risk of postmenopausal endometrial cancer (Sweden). Cancer Causes Control 11:185–192CrossRefPubMed
12.
Salazar-Martinez E, Lazcano-Ponce EC, Lira-Lira GG et al (2000) Case-control study of diabetes, obesity, physical activity and risk of endometrial cancer among Mexican women. Cancer Causes Control 11:707–711CrossRefPubMed
13.
Parazzini F, La Vecchia C, Negri E et al (1999) Diabetes and endometrial cancer: an Italian case-control study. Int J Cancer 81:539–542CrossRefPubMed
14.
Shoff SM, Newcomb PA (1998) Diabetes, body size, and risk of endometrial cancer. Am J Epidemiol 148:234–240PubMed
15.
Maatela J, Aromaa A, Salmi T, Pohja M, Vuento M, Gronroos M (1994) The risk of endometrial cancer in diabetic and hypertensive patients: a nationwide record-linkage study in Finland. Ann Chir Gynaecol Suppl 208:20–24PubMed
16.
Inoue M, Okayama A, Fujita M, Enomoto T, Tanizawa O, Ueshima H (1994) A case-control study on risk factors for uterine endometrial cancer in Japan. Jpn J Cancer Res 85:346–350PubMed
17.
Brinton LA, Berman ML, Mortel R et al (1992) Reproductive, menstrual, and medical risk factors for endometrial cancer: results from a case-control study. Am J Obstet Gynecol 167:1317–1325PubMed
18.
Lawrence C, Tessaro I, Durgerian S, Caputo T, Richart RM, Greenwald P (1989) Advanced-stage endometrial cancer: contributions of estrogen use, smoking, and other risk factors. Gynecol Oncol 32:41–45CrossRefPubMed
19.
Zemla B, Guminski S, Banasik R (1986) Study of risk factors in invasive cancer of the corpus uteri. Neoplasma 33:621–629PubMed
20.
O’Mara BA, Byers T, Schoenfeld E (1985) Diabetes mellitus and cancer risk: a multisite case-control study. J Chronic Dis 38:435–441CrossRefPubMed
21.
Folsom AR, Anderson KE, Sweeney C, Jacobs DR Jr (2004) Diabetes as a risk factor for death following endometrial cancer. Gynecol Oncol 94:740–745CrossRefPubMed
22.
Rubin GL, Peterson HB, Lee NC, Maes EF, Wingo PA, Becker S (1990) Estrogen replacement therapy and the risk of endometrial cancer: remaining controversies. Am J Obstet Gynecol 162:148–154PubMed
23.
Kelsey JL, LiVolsi VA, Holford TR et al (1982) A case-control study of cancer of the endometrium. Am J Epidemiol 116:333–342PubMed
24.
Anderson KE, Anderson E, Mink PJ et al (2001) Diabetes and endometrial cancer in the Iowa women’s health study. Cancer Epidemiol Biomarkers Prev 10:611–616PubMed
25.
Terry P, Baron JA, Weiderpass E, Yuen J, Lichtenstein P, Nyren O (1999) Lifestyle and endometrial cancer risk: a cohort study from the Swedish Twin Registry. Int J Cancer 82:38–42CrossRefPubMed
26.
Coughlin SS, Calle EE, Teras LR, Petrelli J, Thun MJ (2004) Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol 159:1160–1167CrossRefPubMed
27.
Newcomer LM, Newcomb PA, Trentham-Dietz A, Storer BE (2001) Hormonal risk factors for endometrial cancer: modification by cigarette smoking (United States). Cancer Causes Control 12:829–835CrossRefPubMed
28.
Parslov M, Lidegaard O, Klintorp S et al (2000) Risk factors among young women with endometrial cancer: a Danish case-control study. Am J Obstet Gynecol 182:23–29CrossRefPubMed
29.
Hagen A, Morack G, Grulich D (1995) Evaluation of epidemiologic risk factors for endometrial carcinoma based on a case-control study. Zentralbl Gynakol 117:368–374 [in German]PubMed
30.
Feldman S, Cook EF, Harlow BL, Berkowitz RS (1995) Predicting endometrial cancer among older women who present with abnormal vaginal bleeding. Gynecol Oncol 56:376–381CrossRefPubMed
31.
La Vecchia C, Negri E, Franceschi S, D’Avanzo B, Boyle P (1994) A case-control study of diabetes mellitus and cancer risk. Br J Cancer 70:950–953PubMed
32.
Geraci P, Mancuso A, Maggio S, Dardanoni G (1988) Risk factors of endometrial cancer in Palermo. Clin Exp Obstet Gynecol 15:129–133PubMed
33.
Elwood JM, Cole P, Rothman KJ, Kaplan SD (1977) Epidemiology of endometrial cancer. J Natl Cancer Inst 59:1055–1060PubMed
34.
Swerdlow AJ, Laing SP, Qiao Z et al (2005) Cancer incidence and mortality in patients with insulin-treated diabetes: a UK cohort study. Br J Cancer 92:2070–2075CrossRefPubMed
35.
Zendehdel K, Nyren O, Ostenson CG, Adami HO, Ekbom A, Ye W (2003) Cancer incidence in patients with type 1 diabetes mellitus: a population-based cohort study in Sweden. J Natl Cancer Inst 95:1797–1800PubMed
36.
Weiderpass E, Gridley G, Persson I, Nyren O, Ekbom A, Adami HO (1997) Risk of endometrial and breast cancer in patients with diabetes mellitus. Int J Cancer 71:360–363CrossRefPubMed
37.
Wideroff L, Gridley G, Mellemkjaer L et al (1997) Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst 89:1360–1365CrossRefPubMed
38.
Ragozzino M, Melton LJ 3rd, Chu CP, Palumbo PJ (1982) Subsequent cancer risk in the incidence cohort of Rochester, Minnesota, residents with diabetes mellitus. J Chronic Dis 35:13–19CrossRefPubMed
39.
Verlato G, Zoppini G, Bonora E, Muggeo M (2003) Mortality from site-specific malignancies in type 2 diabetic patients from Verona. Diabetes Care 26:1047–1051CrossRefPubMed
40.
Kessler II (1970) Cancer mortality among diabetics. J Natl Cancer Inst 44:673–686PubMed
41.
Adami HO, McLaughlin J, Ekbom A et al (1991) Cancer risk in patients with diabetes mellitus. Cancer Causes Control 2:307–314CrossRefPubMed
42.
Greenland S (1987) Quantitative methods in the review of epidemiologic literature. Epidemiol Rev 9:1–30PubMed
43.
44.
Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539–1558CrossRefPubMed
45.
Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634PubMed
46.
Egger M, Smith GD, Altman DG (2001) Systematic reviews in health care: meta-analysis in context. BMJ, London
47.
Nagamani M, Stuart CA (1998) Specific binding and growth-promoting activity of insulin in endometrial cancer cells in culture. Am J Obstet Gynecol 179:6–12CrossRefPubMed
48.
Lukanova A, Zeleniuch-Jacquotte A, Lundin E et al (2004) Prediagnostic levels of C-peptide, IGF-I, IGFBP -1, -2 and -3 and risk of endometrial cancer. Int J Cancer 108:262–268CrossRefPubMed
49.
Kazer RR (1995) Insulin resistance, insulin-like growth factor I and breast cancer: a hypothesis. Int J Cancer 62:403–406CrossRefPubMed
50.
Nestler JE, Powers LP, Matt DW et al (1991) A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab 72:83–89PubMedCrossRef
51.
Graham JD, Clarke CL (1997) Physiological action of progesterone in target tissues. Endocr Rev 18:502–519CrossRefPubMed
52.
Ferenczy A, Bertrand G, Gelfand MM (1979) Proliferation kinetics of human endometrium during the normal menstrual cycle. Am J Obstet Gynecol 133:859–867PubMed
53.
Key TJ, Pike MC (1988) The dose-effect relationship between ‘unopposed’ oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. Br J Cancer 57:205–212PubMed
54.
Irwin JC, de las Fuentes L, Dsupin BA, Giudice LC (1993) Insulin-like growth factor regulation of human endometrial stromal cell function: coordinate effects on insulin-like growth factor binding protein-1, cell proliferation and prolactin secretion. Regul Pept 48:165–177CrossRefPubMed
55.
Murphy LJ (1994) Growth factors and steroid hormone action in endometrial cancer. J Steroid Biochem Mol Biol 48:419–423CrossRefPubMed
56.
Corocleanu M (1993) Hypothesis for endometrial carcinoma carcinogenesis. Preventive prospects. Clin Exp Obstet Gynecol 20:254–258PubMed
57.
Thiet MP, Osathanondh R, Yeh J (1994) Localization and timing of appearance of insulin, insulin-like growth factor-I, and their receptors in the human fetal mullerian tract. Am J Obstet Gynecol 170:152–156PubMed
58.
Ordener C, Cypriani B, Vuillermoz C, Adessi GL (1993) Epidermal growth factor and insulin induce the proliferation of guinea pig endometrial stromal cells in serum-free culture, whereas estradiol and progesterone do not. Biol Reprod 49:1032–1044CrossRefPubMed
59.
Weiderpass E, Brismar K, Bellocco R, Vainio H, Kaaks R (2003) Serum levels of insulin-like growth factor-I, IGF-binding protein 1 and 3, and insulin and endometrial cancer risk. Br J Cancer 89:1697–1704CrossRefPubMed
60.
Steffes MW, Gross MD, Schreiner PJ et al (2004) Serum adiponectin in young adults-interactions with central adiposity, circulating levels of glucose, and insulin resistance: the CARDIA study. Ann Epidemiol 14:492–498CrossRefPubMed
61.
Dal Maso L, Augustin LS, Karalis A et al (2004) Circulating adiponectin and endometrial cancer risk. J Clin Endocrinol Metab 89:1160–1163CrossRef
Metadata
Title
Diabetes mellitus and risk of endometrial cancer: a meta-analysis
Authors
E. Friberg
N. Orsini
C. S. Mantzoros
A. Wolk
Publication date
01-07-2007
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 7/2007
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-007-0681-5

Other articles of this Issue 7/2007

Diabetologia 7/2007 Go to the issue

Article

Defective IGF2 and IGF1R protein production in embryonic pancreas precedes beta cell mass anomaly in the Goto–Kakizaki rat model of type 2 diabetes

Letter

Response to comment on: Davidson MB (2007) The dilemma of self-monitoring of blood glucose. Diabetologia 50:497–499

Article

Early administration of the glucose-dependent insulinotropic polypeptide receptor antagonist (Pro3)GIP prevents the development of diabetes and related metabolic abnormalities associated with genetically inherited obesity in ob/ob mice

Short Communication

Direct rosiglitazone-induced modifications in insulin secretion, action and clearance: a single-dose hyperglycaemic clamp study

Article

Glucagon receptor antagonism improves islet function in mice with insulin resistance induced by a high-fat diet

Article

Acute nutrient regulation of the unfolded protein response and integrated stress response in cultured rat pancreatic islets
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits